KK2223 Clinical Trials (2026): 1 Studies for T-cell NHL (PTCL or CTCL)
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
1 KK2223 clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 1 indication (including T-cell NHL (PTCL or CTCL)) and 72 total planned enrollment. 1 KK2223 clinical trial is actively recruiting at 4 U.S. sites across 4 states. Most recent activity: NCT07192471 (Sep 2030).
Where to Participate: All KK2223 Trial Sites in the U.S. (4 sites across 4 states)
Every actively recruiting KK2223trial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| CA | Stanford University School of Medicine | Stanford94305 | NCT07192471 | Map |
| MO | Washington University School of Medicine - Oncology Hospital - Public | St Louis63110 | NCT07192471 | Map |
| NY | Memorial Sloan Kettering Cancer Center | New York10021-6007 | NCT07192471 | Map |
| TX | The University of Texas - MD Anderson Cancer Center | Houston77030 | NCT07192471 | Map |
KK2223 clinical trials at a glance: phase × recruitment status
| Phase | recruiting | Total |
|---|---|---|
| P1 | 1 | 1 |
Recruiting KK2223 clinical trials (1)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07192471 | A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma | P1 | T-cell NHL (PTCL or CTCL) | 72 | Sep 2026 |
All KK2223 trials (1)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07192471 | A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma | P1 | recruiting | 72 | Kyowa Kirin, Inc. | Sep 2026 |
KK2223 clinical trials: frequently asked questions
- How many KK2223 clinical trials are there?
- 1 KK2223 clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 1 is actively recruiting participants.
- Are KK2223 clinical trials recruiting in 2026?
- Yes — 1 KK2223 trial is actively recruiting in 2026, with 4 U.S. sites across 4 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is KK2223 being studied for?
- KK2223 is being studied for T-cell NHL (PTCL or CTCL). The trials are grouped by indication on this page.
- What phase is KK2223 in?
- KK2223 clinical trials span 1 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors KK2223 clinical trials?
- The lead sponsor across the most KK2223 trials is Kyowa Kirin, Inc.. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming KK2223as an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: